{'52WeekChange': -0.1233933,
 'SandP52WeekChange': None,
 'address1': 'Yalelaan 62',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.8,
 'askSize': 800,
 'averageDailyVolume10Day': 49375,
 'averageVolume': 123609,
 'averageVolume10days': 49375,
 'beta': 0.780706,
 'beta3Year': None,
 'bid': 13.05,
 'bidSize': 1400,
 'bookValue': 3.95,
 'category': None,
 'circulatingSupply': None,
 'city': 'Utrecht',
 'companyOfficers': [],
 'country': 'Netherlands',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.59,
 'dayLow': 12.87,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.708,
 'enterpriseToRevenue': 6.371,
 'enterpriseValue': 182246928,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 15.076858,
 'fiftyTwoWeekHigh': 20.95,
 'fiftyTwoWeekLow': 10.186,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 12546703,
 'forwardEps': -2.46,
 'forwardPE': -5.4796743,
 'fromCurrency': None,
 'fullTimeEmployees': 87,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.12380999,
 'heldPercentInstitutions': 0.73877,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/merus.nl',
 'longBusinessSummary': 'Merus N.V., a clinical-stage immuno-oncology company, '
                        'engages in developing bispecific antibody '
                        'therapeutics. Its bispecific antibody candidate '
                        'pipeline includes MCLA-128, which is in a Phase II '
                        'clinical trial for the treatment of patients with '
                        'metastatic breast cancer; and Phase I/II clinical '
                        'trial for the treatment of gastric and non-small cell '
                        'lung cancers. The company is also developing MCLA-117 '
                        'that is in Phase I clinical trial for the treatment '
                        'of patients with acute myeloid leukemia; and '
                        'MCLA-158, which is in a Phase I clinical trial for '
                        'the treatment of solid tumors with an initial focus '
                        'on colorectal cancer. In addition, its research and '
                        'development stage bispecific antibody candidates '
                        'include MCLA-129, which is being developed in '
                        'collaboration with Betta Pharmaceuticals Co. Ltd; '
                        'MCLA-145, which is being developed in collaboration '
                        'with Incyte Corporation; and clinical programs to '
                        'explore new potential combination therapies or '
                        'indication. Merus has collaboration with Caris Life '
                        'Sciences to detect NRG1 fusions in cancer patients. '
                        'The company was founded in 2003 and is headquartered '
                        'in Utrecht, the Netherlands.',
 'longName': 'Merus N.V.',
 'market': 'us_market',
 'marketCap': 391479392,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24929296',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -64568000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.59,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '31 30 253 8800',
 'previousClose': 13.64,
 'priceHint': 2,
 'priceToBook': 3.412658,
 'priceToSalesTrailing12Months': 13.685698,
 'profitMargins': -2.25723,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.59,
 'regularMarketDayLow': 12.87,
 'regularMarketOpen': 13.59,
 'regularMarketPreviousClose': 13.64,
 'regularMarketPrice': 13.59,
 'regularMarketVolume': 55119,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 29041500,
 'sharesPercentSharesOut': 0.0089,
 'sharesShort': 258299,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 252579,
 'shortName': 'Merus N.V.',
 'shortPercentOfFloat': 0.0117999995,
 'shortRatio': 1.28,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'MRUS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.521,
 'twoHundredDayAverage': 15.082878,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '42321671-9233-3f73-a2ee-487472589127',
 'volume': 55119,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.merus.nl',
 'yield': None,
 'ytdReturn': None,
 'zip': '3584 CM'}